GBLX - GB Sciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1000
+0.0050 (+5.26%)
At close: 3:42PM EDT
Stock chart is not supported by your current browser
Previous Close0.0950
Open0.1020
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0920 - 0.1060
52 Week Range0.0800 - 0.4400
Volume1,208,992
Avg. Volume619,173
Market Cap25.288M
Beta (3Y Monthly)0.48
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GB Sciences Sells Its Louisiana Medical Marijuana Business At A $32 Million Total Valuation
    PR Newswire

    GB Sciences Sells Its Louisiana Medical Marijuana Business At A $32 Million Total Valuation

    LAS VEGAS, Sept. 17, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX), on Friday, September 13, 2019, filed an 8k announcing the sale of its 50% ownership stake in GB Sciences Louisiana, LLC.  The stake will be purchased by Wellcana Plus LLC, affiliated through its managers with the group which holds the other 50% of the Louisiana operations.  Expected to close by the end of October 2019, the sale is for $16 million to GB Sciences, $7 million in cash at closing, $1 million in cash within 60 days of closing, and the remaining $8 million as an earn out.  The actual proceeds realized through the earn out and the timing of those proceeds will depend upon the profitability of the Louisiana operations. The sale will greatly reduce the current and future burn rate of the Company and allow it to focus on achieving profitability, seeking a DEA license, and implementing GMP, a set of regulations promulgated by the US Food and Drug Administration to ensure quality control in the manufacture of pharmaceuticals, dietary supplements and natural health products among other substances, at its Las Vegas, Nevada location.

  • U.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers
    CNW Group

    U.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers

    U.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers

  • GB Sciences Names Darin Carpenter as Executive Vice President of Cannabis Operations
    CNW Group

    GB Sciences Names Darin Carpenter as Executive Vice President of Cannabis Operations

    LAS VEGAS , Aug. 28, 2019 /CNW/ -- GB Sciences, Inc. (GBLX) today announced the appointment to GB Sciences' executive team of Darin Carpenter as the company's new Executive Vice President for Operations and General Manager, bringing his extensive and nationally-recognized experience streamlining production, improving product quality, and increasing profitability to GBS.

  • GB Sciences Prepares To Launch New Products In Louisiana With Educational Seminars For Doctors And Pharmacists
    PR Newswire

    GB Sciences Prepares To Launch New Products In Louisiana With Educational Seminars For Doctors And Pharmacists

    Education program includes evidence-based review of FDA-registered human clinical trial data supporting the use of cannabis to treat approved medical conditions. LAS VEGAS, Aug. 7, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announced that its subsidiary GB Sciences Louisiana will hold a series of seminars in August, in partnership with state-approved medical cannabis pharmacies and the LSU AgCenter, to further educate Louisiana physicians and pharmacists about the new medical cannabis products that the company will launch in coming months.

  • History Made! GB Sciences Louisiana Announces Medical Cannabis Products Now for Sale for First Time in State History
    PR Newswire

    History Made! GB Sciences Louisiana Announces Medical Cannabis Products Now for Sale for First Time in State History

    BATON ROUGE, La., Aug. 6, 2019 /PRNewswire/ -- GB Sciences Louisiana (GBLX) today announced that its medical cannabis products, developed in partnership with LSU AgCenter's Therapeutic Cannabis Program, are available for sale to qualified patients in the state's nine licensed pharmacies. This is the first time that qualified patients have legal cannabis medicine available under Louisiana law, marking a historic turning point for patients, advocates, and regulators. "This is a watershed moment for our company and the State of Louisiana, reflecting many years of research and development by GB Sciences into the cannabis plant's biopharmaceutical applications," said John Davis, President of GB Sciences Louisiana.

  • GB Sciences Files Novel Patent Application For Chronic Pain Treatments Based On Proprietary Cannabis-Derived Formulations
    PR Newswire

    GB Sciences Files Novel Patent Application For Chronic Pain Treatments Based On Proprietary Cannabis-Derived Formulations

    In the US, chronic pain represents an estimated health burden of between $560 and $650 billion dollars. LAS VEGAS, July 17, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX), through its subsidiary, GBS Global Biopharma, Inc. ("GBS", Ottawa, CANADA), has filed a novel patent application to protect proprietary formulations for chronic pain based on new molecular docking simulations and functional assay data. New pain treatments are a vitally important area of research and development given the widespread rates of addiction and mortality tied to opioids.

  • GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients
    CNW Group

    GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients

    GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients

  • GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies
    PR Newswire

    GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies

    OTTAWA, Ontario, May 28, 2019 /PRNewswire/ -- GBS Global Biopharma, Inc. ("GBS Global"), a Canadian-based subsidiary of GB Sciences, Inc. (GBLX), announced preclinical studies on their proprietary chronic-neuropathic pain formulations in collaboration with the National Research Council ("NRC") Canada under the direction of Dr. Lee Ellis at NRC laboratories in Halifax, Nova Scotia. Growing public and government concerns regarding opioid abuse make novel pain treatments a promising field of research and development.

  • GB Sciences Prepares to Triple Production Capabilities in Its Las Vegas Facility
    PR Newswire

    GB Sciences Prepares to Triple Production Capabilities in Its Las Vegas Facility

    Positioned to Increase Revenue by Approximately $5.6 Million LAS VEGAS , May 14, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) today announced it is nearing completion of $700,000 in power and water ...

  • GB Sciences Louisiana Receives All Approvals and Announces the Opening of the Full Tissue Propagation Cannabis Cultivation at LSU Agricultural Center
    PR Newswire

    GB Sciences Louisiana Receives All Approvals and Announces the Opening of the Full Tissue Propagation Cannabis Cultivation at LSU Agricultural Center

    Increases production and ensures a continuous supply of therapeutic cannabis for Louisiana patients. LAS VEGAS, April 16, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX), a partner in GB Sciences Louisiana, LLC, is announcing that all cultivation operations at LSU Agricultural Center are now open. This will allow a continuous harvest for patients by increasing GB Sciences Louisiana's production capacity 500%.

  • Today: GB Sciences' Use of Controlled Cultivation, Product Formulations and Research Will Be Presented by Dr. Dominick Monaco at Cannabis Conference 2019, As Featured on Cover of Cannabis Business Times
    PR Newswire

    Today: GB Sciences' Use of Controlled Cultivation, Product Formulations and Research Will Be Presented by Dr. Dominick Monaco at Cannabis Conference 2019, As Featured on Cover of Cannabis Business Times

    LAS VEGAS, April 2, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announced that Dr. Dominick Monaco, GB Sciences' Director of Medical Formulations, will be a featured speaker at the Las Vegas Cannabis Conference TODAY, April 2, at 4:40pm. Learn more here.

  • GB Sciences Study Shows Nevada's Cannabis Strain Names Have No Correlation to Active Ingredients
    PR Newswire

    GB Sciences Study Shows Nevada's Cannabis Strain Names Have No Correlation to Active Ingredients

    LAS VEGAS, March 28, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) today announced results from a new study that shows only three chemical varieties of cannabis were sold in the Nevada dispensaries between January 2016 and June 2017-- despite nearly 400 different "strain names" appearing on product packaging. Co-authored by GB Sciences, Chaminade University, Makai Biotechnology and Digipath Labs, and published in the journal Cannabis and Cannabinoid Research, the study reveals extremely low chemical diversity within the cannabis varieties sold in the Nevada market during its medical-only phase.

  • In Case You Missed It: GB Sciences Approved For Full Operations In Main LSU AgCenter Production Facility
    PR Newswire

    In Case You Missed It: GB Sciences Approved For Full Operations In Main LSU AgCenter Production Facility

    With over five times the production capacity, main facility will allow for a perpetual harvest cycle, ensuring a continuous supply of therapeutic cannabis for patients throughout Louisiana. LAS VEGAS, March 26, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) today announced that The LSU Agricultural Center (AgCenter) received confirmation from the Louisiana Department of Agriculture and Forestry (LDAF) that GB Sciences Louisiana is deemed suitable for full-scale operations.

  • Louisiana Agriculture Commissioner Approves GB Sciences To Begin Full Operations In Main LSU AgCenter Production Facility
    PR Newswire

    Louisiana Agriculture Commissioner Approves GB Sciences To Begin Full Operations In Main LSU AgCenter Production Facility

    With over five times the production capacity, main facility will allow for a perpetual harvest cycle, ensuring a continuous supply of therapeutic cannabis for patients throughout Louisiana. LAS VEGAS, March 22, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) today announced that The LSU Agricultural Center (AgCenter) received confirmation from the Louisiana Department of Agriculture and Forestry (LDAF) that GB Sciences Louisiana is deemed suitable for full-scale operations.

  • GB Sciences Launches Global Expansion in Canada with GBS Global Biopharma, Inc.
    PR Newswire

    GB Sciences Launches Global Expansion in Canada with GBS Global Biopharma, Inc.

    Expedites innovative cannabinoid medicine program, covering 60 disease and health conditions including Parkinson's Disease, neuropathic pain and cardiac hypertrophy LAS VEGAS , March 19, 2019 /PRNewswire/ ...

  • GB Sciences Supports the Position of LSU AgCenter: Allegations Made by Commissioner Are Untrue
    PR Newswire

    GB Sciences Supports the Position of LSU AgCenter: Allegations Made by Commissioner Are Untrue

    LSU AgCenter issued the following statement on Friday, March 8th. LAS VEGAS , March 12, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) announces that the Louisiana State University Agricultural Center ...

  • GB Sciences Declares A "Research Revolution" At Its "2018 Innovation In Medical Cannabis Therapies" Symposium
    PR Newswire

    GB Sciences Declares A "Research Revolution" At Its "2018 Innovation In Medical Cannabis Therapies" Symposium

    On November 9th, GB Sciences hosted an open mic-dialogue with key stakeholders in the cannabis industry that focused on addressing medical patients' needs through improved standardization and innovation of future medical cannabis products. LAS VEGAS, Dec. 14, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces the success of its first annual, "Innovation in Medical Cannabis Therapies" (IMCT) Symposium, held on Friday, November 9th at the "Keep Memory Alive" Event Center at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada. Throughout the day's program, there was an emerging sense of heightened responsibility on the part of the cannabis industry to better address medical cannabis patients' needs through research and development of medical cannabis products that are better standardized, more easily-dosed, and made more widely-available to cannabis patients at a fair price.